Why—and When—to Use a CDMO

What is a CDMO? This article answers when and why to use a Contract Development and Manufacturing Organization (CDMO), and it is the first part of our “Best Practices in the CDMO Selection Process” series.

Published on:
August 25, 2022

Pharmaceutical development companies of all sizes frequently outsource their Active Pharmaceutical Ingredient (API) manufacturing to CDMOs for various reasons, including:

  • limited internal know-how and capacity to manufacture API according to Good Manufacturing Practice (GMP), or
  • to reduce costs and timelines.

In this article, we will explore three common reasons why a company might consider engaging a CDMO.

Resource optimization

Early clinical development naturally leads to a fast cycling of projects as candidate molecules are identified and prioritized. Providing staff and capital required for this fluctuation in demand is at the discretion of the company. If a company does invest capital and internal resources to expand its manufacturing capability, it’s best to keep those assets active to offset their high cost.

While cost reduction may seem like a guarantee with a CDMO, a company can truly maximize its savings with a well-planned CDMO selection strategy.
Greater technical expertise and robust infrastructure

Small virtual biotech companies and early-stage clinical companies might have limited internal capabilities and the technical expertise required to manufacture an API. Engaging a CDMO with applicable existing infrastructure and expertise can benefit the company financially while also improving overall product quality and timelines.

Cost reduction

While cost reduction may seem like a guarantee with a CDMO, a company can truly maximize its savings with a well-planned CDMO selection strategy. Initially, a company needs to ensure it’s utilizing its current internal resources to the maximum and only then identify what should be outsourced to a CDMO thus cutting unnecessary spending. More importantly, a carefully planned CDMO selection process can help to identify a CDMO offering the best overall value to the company. While such an identification, evaluation and selection process is not trivial, overall savings can be substantial if the entire process is carried out well.

If you are deciding to outsource your manufacturing or simply looking to obtain insight into the overall CDMO landscape in order to identify the right CDMO for your project, we are here to assist. Our expert team has been helping companies choose the right CDMO for more than a decade.

Related news

Blog November 17, 2023
Misconceptions About Patient-Centric Co-Design
Many people have misconceptions about patient-centric co-design, and these misconceptions are holding companies back.
Co-Design Digital Health MedTech Patient Centricity Pharma
Blog November 2, 2023
The Impact of New Treatment Approvals in Oncology on Relative Survival Rates for EU Patients
This article explores the relationship between the number of new cancer treatment approvals and the five-year relative survival of cancer patients across the European Union (EU).
Oncology Pharma
Multimedia October 18, 2023
The Process of CDMO Selection for Antibody Development: Matching Capabilities to Need
In this webinar, you'll learn how to identify key solution features, define patient experience expectations, generate evidence, and more!
Blog October 16, 2023
How to Co-Design a Solution with Patients to Meet Their Needs
To learn how you can benefit from a co-design approach and how to get started, we spoke with two experts on patient engagement and co-design.
Digital Health MedTech Patient Centricity Patient Engagement Pharma
Events October 11, 2023
ISPOR Europe
Will we see you at ISPOR Europe 2023? We'll be presenting on topics including Lupus, value-based contracts, HEOR trends and more.
HEOR Research and Development
Blog October 9, 2023
Inflation Reduction Act and Pharma – Navigating Uncertainty
What's the impact of the Inflation Reduction Act on small biotechs, mid-size companies and large pharma players, and how can they prepare?
Biotech Pharma
Publications September 21, 2023
Essential Elements of Technology Transfer
Peter Alexander, Senior Consultant, CMC, co-authored an article about technology transfer categories, essential elements, and documentation.
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.